Preview Newsletter

XARELTO Media Monitoring – Week of 9-11-15

Plaintiff Attorney Press Releases

Morgan & Morgan Attorneys Prepare for Xarelto Lawsuits in 2016
Sep 8, 2015 | University Chronicle
By Morgan & Morgan

Bellwether trials in the Xarelto multidistrict litigation (MDL) were recently scheduled for Fall 2016. On June 22, 2015 Judge Eldon E. Fallon, overseeing the Xarelto MDL in U.S. District Court for the Eastern District of Louisiana*, announced an updated timetable for a group of consolidated lawsuits against the makers of Xarelto for alleged injuries related to the anticoagulant drug’s use. The first bellwether trial is scheduled for August 1, 2016. Three additional bellwethers will follow on August 22, 2016, September 12, 2016, and October 17, 2016**.
Xarelto Lawsuit Update: New Facts About Xarelto Litigation
Sep 8, 2015 | WCIV-TV
By Marc Goldich

BloodThinnerHelp.com reports today on the facts about the ongoing Xarelto litigation. Xarelto, rivaroxaban, was first approved by the Food and Drug Administration (FDA) in 2011 to help prevent blood clots and deep vein thrombosis in patients who have recently undergone hip or knee replacement surgery, to treat patients who suffer from atrial fibrillation, to treat stent thrombosis in patients with acute coronary syndrome, and for the general purpose of reducing blood clots. Xarelto is manufactured by Bayer AG and Johnson&Johnson’s pharmaceutical unit, Janssen Pharmaceuticals.
Xarelto Lawsuit Update: Xarelto Settlements May Take Place in 2016
Sep 10, 2015 | KBMT-TV
By Marc Goldich

BloodThinnerHelp.com reports today on the new timeline of estimated Xarelto settlements. The Xarelto lawsuits have been in the process for more than a year now and progress is starting to be made.
The Meldofsky Firm Reports That Xarelto Law Suits Continue To Spiral With 400 New Cases In One Month
Sep 11, 2015 | KSLA-TV
By The Meldofsky Firm LLC

The Meldofsky Firm has published a new briefing on the latest state of the ever-expanding class-action law suit against the manufacturers of the allegedly dangerous blood-thinning drug.
Xarelto product liability lawsuit filings on the rise, says funding firm
Sep 11, 2015 | JusticeNewsFlash.com

Product liability lawsuits filed over alleged defects linked to the blood-thinning medication Xarelto are on the rise, a funding firm says. As reported on Yahoo! Finance, New Jersey based lawsuit funding firm Fair Rate Funding, says the number of claims filed in the Philadelphia Court of Common Pleas has arisen to more than 300 cases in recent months.

Plaintiff Attorney Blog Posts

Calif. Woman Adds Xarelto Bleeding Lawsuit to MDL
Sep 7, 2015 | Top Class Actions
By Melissa LaFreniere

A California resident has joined the growing Xarelto bleeding multidistrict litigation (MDL) centralized in Louisiana. Plaintiffs Valerie T. has added her Xarelto lawsuit to the Xarelto MDL, which is addressing the complaints of many plaintiffs who claim that they were not warned of the severe and, in some cases, life-threatening side effects of the blood thinner.
Louisiana Woman Sues Xarelto Manufacturers over Life-threatening Bleeding
Sep 8, 2015 | Danziger & De Llano LLP

A woman from Louisiana is suing the manufacturers of the prescription medication Xarelto over allegations that she experienced life-threatening bleeding after using the product. Glenda Froelich has filed a suit on 12th May in the United States District Court for the Eastern District of LA. Froelich has named the following companies, which are involved in the design, development, manufacture and marketing of Xarelto, as defendants: Janssen Research and Development; Janssen Pharmaceuticals Incorporated; Janssen Ortho; Bayer Healthcare Pharmaceuticals Incorporated; Bayer AG; Bayer Healthcare AG; Bayer Corporation; Bayer Pharma; Bayer Healthcare Pharmaceuticals Incorporated; and Bayer Healthcare LLC. Froelich accuses the defendants of fraud and negligence.
New Study: Xarelto No Safer than Warfarin in Elderly
Sep 9, 2015 | Lopez McHugh LLP

Janssen Pharmaceuticals and Bayer have long insisted their blood-thinning drug Xarelto is a safer, more reliable alternative to the decades-old warfarin. However, a new study recently published in the American Heart Association’s journal Circulation suggests the popular “new-age” anticoagulant may be no safer than warfarin in terms of bleeding in elderly patients.
Side Effects of Xarelto Gastrointestinal Bleeding
Sep 9, 2015 | Meldofsky Firm

The new generation blood thinner drug Xarelto (Rivaroxiban) carries some very serious and potentially deadly side effects, including gastrointestinal bleeding (also known as GI bleeds.) When taking an anti-coagulant drug like Xarelto, gastrointestinal bleeds can occur both in the upper and lower GI tract, posing a serious risk to the patient. If left untreated, the gastrointestinal bleed may continue unabated, ultimately reaching a critical point when blood loss becomes severe.Regarded as a relatively common complication of Xarelto, gastrointestinal bleeding can result in hospitalization and in some cases, death.
Florida Woman Files Xarelto Lawsuit Over Bleeding Injuries
Sep 9, 2015 | Top Class Actions
By Amanda Antell

A Florida woman filed a Xarelto lawsuit against Jansen Pharmaceuticals and Bayer Pharmaceuticals, for allegedly causing her to suffer from internal bleeding. Plaintiff Donna M. claims in her Xarelto lawsuit that as a direct result of using the defendants’ anticoagulant, Xarelto, she developed sudden internal bleeding injuries and had to hospitalized.
Xarelto Bleeding Lawsuit (Video)
Sep 9, 2015 | YouTube
By The Cochran Firm

The Cochran Firm published a video on YouTube that reviews the alleged side effects of Xarelto and implores viewers to contact the law firm. Video: https://www.youtube.com/watch?v=wwt9p1yvB4E
Medical Malpractice Over Medication
Sep 10, 2015 | Xarelto Lawsuit Information

These days medical malpractice has become another every day form of litigation. Given the recent news that’s come to light over the negative effects of Xarelto (rivaroxaban) mainly do to the incorrect dosing resulting in harm and death. Some victims are left to wonder if they have any ground to file a medical malpractice suit against their doctor who prescribed them the drug in the first place.
New Xarelto Lawsuits Filed in 2015
Sep 11, 2015 | Xarelto Problems

21 cases from 10 districts over the blood-thinning drug Xarelto were consolidated into a multidistrict litigation (“MDL”) for pretrial proceedings before Judge Fallon in New Orleans. Meanwhile, more Xarelto lawsuits continue to mount, with 86 suits pending, according to the Judicial Panel on Multidistrict Litigation’s January 15, 2015 monthly report.
Xarelto Lawsuit Might Just Settle In 2016
Sep 11, 2015 | Xarelto Lawsuit Information

The very first stage of the Xarelto suits was the filing of Xarelto grievances in various national and state authorities round the nation. Various sufferers have filed these charges round the state who allege that Xarelto caused them hurt somehow. The charges identify the damage, pain, and bearing the plaintiff put and summarize the legal foundation for a Xarelto suit. Merging cases into an MDL saves judicial resources and expedite cases. An MDL additionally enables attorneys from both sides to focus more on the discovery procedure as well as the cases before resolution discussions and the first trials. This whole procedure typically takes about a complete year.
Xarelto Bleeding Injury Multidistrict Litigation Adds Another Lawsuit
Sep 11, 2015 | Top Class Actions
By Tamara Burns

A Tennessee resident is the newest plaintiff to join the multidistrict litigation (MDL) against Janssen Pharmaceuticals and Johnson & Johnson’s anticoagulant drug, Xarelto. Plaintiff Barbara M. joins thousands of plaintiffs in the Xarelto multidistrict litigation alleging the new generation blood thinner causes serious internal bleeding injuries.

Plaintiff Attorney Press Releases & Blogs - Canadian Litigation

As Xarelto Lawsuits Mount in U.S., Health Canada Announces Safety Review, Bernstein Liebhard LLP Reports
Sep 8, 2015 | PR Leap
By Bernstein Liebhard LLP

As Xarelto bleeding lawsuits (http://www.xareltolawsuit2015.com/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that regulators in Canada recently announced that they were investigating reports of liver injuries potentially associated with the new-generation blood thinner. According to a Health Canada notification issued on August 26th, the country's Vigilance Program has received 61 reports of liver injuries in patients taking Xarelto, while World Health Organization's (WHO) database showed 431 cases of liver injury. In 23 of those cases, Xarelto was the only drug used in 23 of the incidents noted in the WHO database.
Xarelto Lawsuit Update: Canadian Government Launches Xarelto Investigation
Sep 10, 2015 | KCEN-TV
By Marc Goldich

BloodThinnerHelp.com reports on international investigations that have been launched on Xarelto. While the number of Xarelto lawsuits in the United States court system has been steadily growing, regulators in Canada have recently announced investigations into reports of liver injuries that may be associated with Xarelto usage. A Health Canada document released on August 26 reports that they have received 61 reports of liver injuries in patients taking Xarelto and the World Health Organization’s (WHO) database showed 431 incidences of liver injury and in 23 of these cases, Xarelto was the only drug the patient was using.
Canadian Xarelto Review Prompted by Liver Injury Reports
Sep 11, 2015 | Bernstein Liebhard LLP
By Sandy Liebhard

Health Canada recently revealed that it had undertaken a safety review of Xarelto, after the blood thinner had been named in dozens of liver injury reports. So far, the regulator has been unable to establish a clear link between Xarelto and those injuries, but it is encouraging doctors and patients to report any liver-related harmful affects that may be tied to its use.
Canadian Government Launches Xarelto Investigation
Sep 10, 2015 | The National Law Review
By Stefanie Colella-Walsh

Xarelto (rivaroxaban) is a blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in July 2011 to prevent strokes in patients who received hip and knee replacements. In November 2011, the approval was expanded to any patients with atrial fibrillation (irregular heartbeat). Xarelto has been widely prescribed, with millions of people taking the medication since it entered the market.

Plaintiff Attorney Press Releases

Morgan & Morgan Attorneys Prepare for Xarelto Lawsuits in 2016

Sep 8, 2015 | University Chronicle

By Morgan & Morgan

Orlando, FL (PRWEB) September 08, 2015
Bellwether trials in the Xarelto multidistrict litigation (MDL) were recently scheduled for Fall 2016.
On June 22, 2015 Judge Eldon E. Fallon, overseeing the Xarelto MDL in U.S. District Court for the Eastern District of Louisiana*, announced an updated timetable for a group of consolidated lawsuits against the makers of Xarelto for alleged injuries related to the anticoagulant drug’s use. The first bellwether trial is scheduled for August 1, 2016. Three additional bellwethers will follow on August 22, 2016, September 12, 2016, and October 17, 2016**.
Morgan & Morgan’s Complex Litigation Group has filed personal injury and death claims on behalf of Xarelto patients and the firm will play a leadership role in the Xarelto MDL as a member of the Plaintiff’s Steering Committee, a group of attorneys that coordinates and directs plaintiff claims in an MDL.
Michael Goetz, an attorney at Morgan & Morgan’s Tampa office, was appointed by Judge Fallon to the Plaintiff’s Steering Committee***. Goetz describes the extensive work of the committee as currently “reviewing millions of pages of documents produced by the defendants”. He adds that, “[w]e believe these documents will support our contention that the risk of suffering a major bleeding event while on Xarelto is much greater than warned about by the manufacturer.”
Plaintiffs in the Xarelto MDL similarly allege that their use of the drug has resulted in serious side effects such as internal bleeding and bleeding that cannot be stopped. They claim that Janssen Pharmaceuticals and Bayer Healthcare did not adequately warn patients and doctors about the risks of life-threatening bleeding with Xarelto.
“Our clients have suffered life-changing or ending injuries as a result of the dangerous effects of this drug and we are firmly committed to bringing them justice,” said Mr. Goetz.
Goetz and the Morgan & Morgan legal team continues to evaluate potential Xarelto claims on behalf of consumers who used the drug and suffered abnormal bleeding. But with trial dates now set for late 2016, the time remaining to file a claim is growing shorter daily. Claimants who do not act soon may miss out on the Xarelto MDL entirely.
For more information regarding the Xarelto MDL, contact Morgan & Morgan here.
http://www.ssuchronicle.com/2015/09/08/morgan-morgan-attorneys-prepare-for-xarelto-lawsuits-in-2016/

Return to headline | Return to top
Xarelto Lawsuit Update: New Facts About Xarelto Litigation

Sep 8, 2015 | WCIV-TV

By Marc Goldich

September 08, 2015 – /PressAdvantage/ – BloodThinnerHelp.com reports today on the facts about the ongoingXarelto litigation. Xarelto, rivaroxaban, was first approved by the Food and Drug Administration (FDA) in 2011 to help prevent blood clots and deep vein thrombosis in patients who have recently undergone hip or knee replacement surgery, to treat patients who suffer from atrial fibrillation, to treat stent thrombosis in patients with acute coronary syndrome, and for the general purpose of reducing blood clots. Xarelto is manufactured by Bayer AG and Johnson&Johnson’s pharmaceutical unit, Janssen Pharmaceuticals.
Xarelto’s Dangerous Side Effects:
Xarelto lawsuits are currently being filed all based on several common allegations, including the fact that there is no existing reversal drug or antidote for Xarelto and dialysis, physically filtering the drug form the system, is not a solution for Xarelto usage and will not enable blood clotting and coagulation. Traditional blood thinners such as Warfarin come with an antidote, a doctor can administer Vitamin K in the event of an internal bleeding injury and the blood will begin to clot again. If a patient taking Xarelto suffers from an internal bleeding injury, there is no way to stop the bleeding.
In a Phase III study performed on individuals taking Xarelto, the results showed that 73% of the 16,041 individuals participating suffered from an adverse side effect of the drug such as internal bleeding or anemia. The FDA issued a warning in August 2013 that made the public aware that stopping a Xarelto regimen prematurely leads to a higher risk of blood clots and despite this warning, in 2013 Xarelto manufacturers profited with $1.4 billion of Xarelto sales.
Xarelto Lawsuits Filed By Victims:
The first Xarelto lawsuit was filed in January 2014. The lawsuit alleged that Xarelto was the cause of the patient’s death because of an uncontrollable internal bleeding incident brought on by the drug. Since then, most of the lawsuits filed allege that Xarelto caused the individual uncontrollable internal bleeding which resulted in death or other serious injury. Some of the commonly reported injuries are gastrointestinal bleeding, internal bleeding, brain hemorrhages, pulmonary embolisms, epidural hematoma, stroke, and heart attacks.
Due to the volume of lawsuits filed, they have recently been consolidated into a Federal Multidistrict Litigation panel. The MDL, formed in December 2014, is based out of New Orleans, Lousiana and is presided over by Judge Eldon Fallon.
In addition to the Federal MDL, a number of lawsuits filed in Pennsylvania have been consolidated into a mass tort program in Philadelphia.
“As more lawsuits are filed in the MDL, we expect even more people to come forward,” Xarelto attorney Marc Goldich said. “We encourage anyone who believes they were harmed by the drug to come forward.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.abcnews4.com/story/29983381/xarelto-lawsuit-update-new-facts-about-xarelto-litigation

Return to headline | Return to top
Xarelto Lawsuit Update: Xarelto Settlements May Take Place in 2016

Sep 10, 2015 | KBMT-TV

By Marc Goldich

September 10, 2015 – /PressAdvantage/ – BloodThinnerHelp.com reports today on the new timeline of estimated Xarelto settlements. The Xarelto lawsuits have been in the process for more than a year now and progress is starting to be made.
Xarelto Lawsuit Timeline:
The first phase of the Xarelto lawsuits was the filing of Xarelto complaints in various state and federal jurisdictions around the country. These complaints have been filed by various victims around the country who allege that Xarelto caused them harm in some way. The complaints outline the legal basis for a Xarelto lawsuit and identify the damage, pain, and suffering the plaintiff endured.
When a mass tort has multiple filings, either the plaintiff or the defense can request that the court consolidate the claims. In December 2014 all of the federally filed Xarelto complaints were transferred into a multidistrict litigation, or an MDL, in the Eastern District of Louisiana in New Orleans under presiding District Judge Eldon Fallon. Consolidating cases into an MDL expedite cases and saves judicial resources. An MDL also allows lawyers from both sides to focus more on the cases and the discovery process before the initial trials and settlement talks. This entire process usually takes about a full year.
Currently, there are about 1,200 cases filed in the Xarelto MDL and based on the number of prescriptions issued and the adverse event rate, the number of lawsuits filed is expected to continue to rise as litigation moves forward.
We estimate that settlement negotiations will begin to take place at the earliest in 2016. If the defendants decide to settle these lawsuits, they may do so via a global or inventory settlement. In a group of lawsuits regarding a blood thinner similar to Xarelto, Pradaxa, the manufacturers of the drug settled 4,000 cases for $650 million. If no Xarelto settlement is reached in 2016, the trials will continue to be scheduled.
Xarelto’s Dangerous Anticoagulant Effects:
These Xarelto cases are being brought to court because the plaintiffs allege that Xarelto was the cause of their serious adverse events such as uncontrollable internal bleeding which lead to severe injuries or death. Xarelto is a part of a new class of blood thinners, Xa inhibitors, which block thrombin in the blood, the chemical in the blood that allows the blood to clot. In the event of an internal bleeding injury, there is no antidote for Xarelto’s effects, so if a patient is internally bleeding, there is no way to stop the bleeding. Most of the Xarelto lawsuits allege that the drug’s manufacturers were aware of these additional risks associated ith Xarelto and failed to adequately warn patients and doctors.
“We strongly encourage anyone who may have been harmed by Xarelto to contact us immediately,” said experienced Xarelto attorney Marc Goldich. “Our lawyers are dedicated to fighting for justice.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.12newsnow.com/story/30003116/xarelto-lawsuit-update-xarelto-settlements-may-take-place-in-2016

Return to headline | Return to top
The Meldofsky Firm Reports That Xarelto Law Suits Continue To Spiral With 400 New Cases In One Month

Sep 11, 2015 | KSLA-TV

By The Meldofsky Firm LLC

The Meldofsky Firm has published a new briefing on the latest state of the ever-expanding class-action law suit against the manufacturers of the allegedly dangerous blood-thinning drug.
Beverly Hills, USA – September 11, 2015 /MarketersMedia/ —
Xarelto is a blood thinning drug designed to help people with blood clotting disorders and other related conditions, and is approved by the FDA. Unlike other blood thinning drugs however, Xarelto has no known antidote, and users have been injured or even died as a result of intestinal and rectal bleeding, blood clots, uncontrolled bleeding events and even brain hemorrhages. The Meldofsky Firm has created a resource center, Xarelto Injury Lawsuits, to report on the development of the cases. Their latest report is their most dramatic yet, with more than 400 cases being added in just four weeks during August.
The Meldofsky Firm has reported that the Johnson & Johnson subsidiary, Janssen Pharmaceuticals and Bayer Healthcare Pharmaceutical are now being sued by 1,230 people after an increase of more than four hundred in just four weeks. This represents a near exponential rise, with just 500 cases reported in June and 800 in July.
The cases have been consolidated into the existing MDL 2592 case, which is now proceeding in the Court of Louisiana as a multi-district litigation case. This means that victims from everywhere in the United States can come forward together to obtain compensation. Meldofksy predict many more will come forward.
A spokesperson for Xarelto Injury Lawsuits explained, “This case identifies strongly as one on an upward spiral- with more cases added each month than in the month before. This month’s case load increased by over one hundred on the previous month, which means more victims are becoming aware of the action and want to see themselves represented. Leading nationwideXarelto lawyers Meldofsky Firm focuses on this form of representation, which is why we are raising awareness of the case: to help more victims find justice.”
About Xarelto Injury Lawsuits: Xarelto Injury Lawsuits is an online resource center dedicated to keeping the public up to date with ongoing developments of the case against the manufacturers of the blood thinning drug Xarelto. The site is provided by The Meldofsky Firm, who focuses in defective device and dangerous drug injury cases, helping clients seek compensation following an injury or wrongful death as a result of Xarelto or other medication.
For more information about us, please visit http://xareltoinjurylawsuits.info/
http://www.ksla.com/story/30009620/the-meldofsky-firm-reports-that-xarelto-law-suits-continue-to-spiral-with-400-new-cases-in-one-month

Return to headline | Return to top
Xarelto product liability lawsuit filings on the rise, says funding firm

Sep 11, 2015 | JusticeNewsFlash.com

New Jersey – Product liability lawsuits filed over alleged defects linked to the blood-thinning medication Xarelto are on the rise, a funding firm says. As reported on Yahoo! Finance, New Jersey based lawsuit funding firm Fair Rate Funding, says the number of claims filed in the Philadelphia Court of Common Pleas has arisen to more than 300 cases in recent months.
The number of lawsuits are also stated to be on the rise in the multidistrict litigation in Louisiana totaling more than 400 cases in US District Court. Some sources report that the total number of Xarelto lawsuits are over 1,200 nationwide.
The claims have been filed against Janssen Pharmaceutical Division, a subsidiary of Bayer and Johnson & Johnson. The lawsuits allege that use of the blood thinner has been linked to serious health problems that in some cases can prove fatal.
Fair Rate Funding provides legal financial support for plaintiffs who have retained an attorney and are involved in personal injury lawsuits for Xarelto cases and other types of claims.
To learn more about product liability lawsuit Justice News Flash follow our product liability lawsuits.
http://www.justicenewsflash.com/2015/09/09/xarelto-product-liability-lawsuit-filings-on-the-rise-says-funding-firm_20150909135524.html

Return to headline | Return to top

Plaintiff Attorney Blog Posts

Calif. Woman Adds Xarelto Bleeding Lawsuit to MDL

Sep 7, 2015 | Top Class Actions

By Melissa LaFreniere

A California resident has joined the growing Xarelto bleeding multidistrict litigation (MDL) centralized in Louisiana.
Plaintiffs Valerie T. has added her Xarelto lawsuit to the Xarelto MDL, which is addressing the complaints of many plaintiffs who claim that they were not warned of the severe and, in some cases, life-threatening side effects of the blood thinner.
Plaintiffs who have joined the Xarelto MDL allege the medication caused injuries, including: gastrointestinal bleeding, pulmonary bleeding, internal bleeding and deep vein thrombosis.
Xarelto Bleeding Complications Overview
The U.S. Food and Drug Administration approved Xarelto in 2011 to treat atrial fibrillation and to be used as a blood clot treatment for patients after knee or hip replacement surgery.
The “new” blood thinner was marketed by using direct-to-consumer advertising, which encouraged patients to ask their physician about Xarelto. Within just a few years, Xarelto gained in popularity as manufacturers claim that it’s the #1 blood thinner in its class, with 11 million prescriptions in the U.S. alone.
Xarelto was marketed to consumers as a “more convenient” blood thinner when compared to the traditional anticoagulant Warfarin (Coumadin). Xarelto manufacturers claimed that consumers taking the new blood thinner would not have any dietary restrictions or have to endure regular blood testing.
However, the FDA began receiving reports of serious Xarelto internal bleeding side effects within a few months of being on the market. In just a few years, the federal agency has received thousands of adverse event reports concerning Xarelto side effects; hundreds of those Xarelto injury reports claim Xarelto caused a hemorrhage related death.
Xarelto Bleeding Risks
In a recent study published in the British Medical Journal, researchers set out to compare the relatively new blood thinner to the Warfarin, which has been on the market for decades.
The Xarelto study followed more than 45,000 patients on an anticoagulant as they tried to determine if either medication posed an increased risk of bleeding complications.
Researchers found that those patients taking Xarelto were twice as likely to experience gastrointestinal bleeding than those patients taking Warfarin.
Other commonly reported Xarelto side effects include:
Low blood pressure
Abnormal liver function
Rectal bleeding
Brain hemorrhaging
Bruising
Rapid heartbeat
Reduced platelet levels
Nose bleeds
Dizziness
Hemorrhaging in the eyes
Xarelto Internal Bleeding Lawsuits
Although the risk of a bleeding event could occur with taking any blood thinner, those who have filed Xarelto lawsuits claim they were unaware that should excessive bleeding occur, there would be no reversal agent to get it under control.
Unlike Coumadin consumers who can be given a dose of Vitamin K to stop a bleeding event, Xarelto patients must endure multiple blood transfusions, as the only way to stop the Xarelto bleeding side effects is to get the medication out of the blood system.
In general, plaintiffs who have filed Xarelto lawsuits allege that Johnson & Johnson and it’s subsidiary Janssen Pharmaceuticals along with Bayer did not adequately warn Xarelto consumers that there is no antidote for Xarelto bleeding.
At this point, Xarelto manufacturers face several hundred complaints, but the MDL is expected to reach more than one thousand claims before the trial begins.
The Xarelto Bleeding MDL is In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL No. 2592, in the U.S. District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/144462-calif-woman-adds-xarelto-bleeding-lawsuit-to-mdl/

Return to headline | Return to top
Louisiana Woman Sues Xarelto Manufacturers over Life-threatening Bleeding

Sep 8, 2015 | Danziger & De Llano LLP

New Orleans, Louisiana – A woman from Louisiana is suing the manufacturers of the prescription medication Xarelto over allegations that she experienced life-threatening bleeding after using the product.
Glenda Froelich has filed a suit on 12th May in the United States District Court for the Eastern District of LA. Froelich has named the following companies, which are involved in the design, development, manufacture and marketing of Xarelto, as defendants: Janssen Research and Development; Janssen Pharmaceuticals Incorporated; Janssen Ortho; Bayer Healthcare Pharmaceuticals Incorporated; Bayer AG; Bayer Healthcare AG; Bayer Corporation; Bayer Pharma; Bayer Healthcare Pharmaceuticals Incorporated; and Bayer Healthcare LLC. Froelich accuses the defendants of fraud and negligence.
According to the lawsuit, Froelich began using Xarelto, which is also called rivaroxaban, after her doctor prescribed the drug in 2013 December to treat her atrial fibrillation (irregular heartbeat). In 2014 May, the plaintiff experienced heavy internal bleeding, the suit claims. She also suffered permanent injuries because of her Xarelto use, the complaint states.
Froelich alleges that the defendant pharmaceutical firms failed to adequately warn patients and doctors regarding the risks involved in the use of Xarelto. She says the drug is unreasonably dangerous and defective. Xarelto does not have any known antidote to stop uncontrollable bleeding, Froelich says.
In her lawsuit, Froelich is asking for unspecified monetary damages for: physical pain and suffering; medical costs; emotional distress; permanent injuries; court costs; and attorney’s fees. She is also seeking an undisclosed amount in punitive damages.
The United States Food & Drug Administration (FDA) approved Xarelto initially as a blood thinner medication for patients recovering from hip or knee replacement surgery. Then the agency also approved it to treat blood clot formations in patients suffering from atrial fibrillation and to prevent repeating blood clots.
Atrial fibrillation (AF or AFib) is an irregular or quivering heart beat (arrhythmia) which could lead to severe blood clots, heart failure, stroke, and other cardiac problems. Studies say almost 2.7 million individuals in the United States are suffering from atrial fibrillation.
Xarelto has several serious side effects, including: abdominal bleeding; brain hemorrhage; reduced platelet levels; and abnormal liver function. The most dangerous adverse effect of this blood thinner is uncontrollable and life-threatening bleeding. As of now, no antidote is available to stop such bleeds. The manufacturers of the drug have not yet released information for the medical community on how this problem has to be treated.
http://dandell.com/louisiana-woman-sues-xarelto-manufacturers-over-life-threatening-bleeding/

Return to headline | Return to top
New Study: Xarelto No Safer than Warfarin in Elderly

Sep 9, 2015 | Lopez McHugh LLP

Janssen Pharmaceuticals and Bayer have long insisted their blood-thinning drug Xarelto is a safer, more reliable alternative to the decades-old warfarin. However, a new study recently published in the American Heart Association’s journal Circulation suggests the popular “new-age” anticoagulant may be no safer than warfarin in terms of bleeding in elderly patients.
Xarelto was approved by the U.S. Food and Drug Administration in 2011 for use in patients who have undergone certain surgeries or have irregular heartbeats. Over the past four years, Xarelto has grown to be the best selling new oral anticoagulant, or NOAC. According to the drug’s official website, Xarelto has been prescribed to over 11 million patients in the United States.
But as Xarelto users are now finding out, new-age does not necessarily mean new benefits. Indeed, plaintiffs in Xarelto lawsuits claim Janssen and Bayer’s blood thinner can cause the same severe bleeding as warfarin, but with one important difference—there is currently no antidote to reverse bleeding caused by Xarelto. Warfarin, on the other hand, can be counteracted with doses of vitamin K. Xarelto lawsuits allege that Xarelto’s manufacturers purposely concealed information about the bleeding risks of their drug, putting profits before patient safety.
The new study, carried out by France’s National Health Insurance Strategy and Research Department, evaluated data from three groups of patients: 19,713 warfarin users; 8,433 Pradaxa users; and 4,651 Xarelto users. Anticoagulants were administered to treat patients’ nonvalvular atrial fibrillation (in other words, to prevent stroke). The researchers found no variation in the rates of bleeding across patient groups during the first 90 days of treatment.
Xarelto’s lack of clear advantages over warfarin, coupled with the absence of a reliable reversal agent, has led many patients to file Xarelto lawsuits. Earlier this year, over 100 of these Xarelto lawsuits were consolidated in a multidistrict litigation in Louisiana, despite fierce opposition from Bayer and Johnson & Johnson. At least 100 more Xarelto lawsuits have since been entered into the multidistrict litigation.
Speak to your doctor about any health risks your medications may pose. If you or a loved one experienced severe bleeding after using Xarelto, contact Lopez McHugh today for a free consultation with one of our experienced Xarelto attorneys.
http://lopezmchugh.com/2015/09/09/new-study-xarelto-no-safer-warfarin-elderly/index.html

Return to headline | Return to top
Side Effects of Xarelto Gastrointestinal Bleeding

Sep 9, 2015 | Meldofsky Firm

The new generation blood thinner drug Xarelto (Rivaroxiban) carries some very serious and potentially deadly side effects, including gastrointestinal bleeding (also known as GI bleeds.)
When taking an anti-coagulant drug like Xarelto, gastrointestinal bleeds can occur both in the upper and lower GI tract, posing a serious risk to the patient. If left untreated, the gastrointestinal bleed may continue unabated, ultimately reaching a critical point when blood loss becomes severe.
Regarded as a relatively common complication of Xarelto, gastrointestinal bleeding can result in hospitalization and in some cases, death.
What is Xarelto and How Does it Cause GI Bleeds?
Xarelto is a blood thinner medication known as a Xa inhibitor. This drug works by inhibiting thrombin, a substance that’s required to allow for clotting.
While many think of blood clots as a negative occurrence, clotting is actually required in order to survive an injury or ailment that involves blood loss. The red blood cells clump together, forming a clot, which prevents further blood loss by essentially plugging up the damage in the capillary, vessel or vein. When blood clotting is no longer possible due to a Xa inhibitor such as Xarelto, the body has no mechanism through which to stop the flow of blood.
This makes Xarelto and gastrointestinal bleeding a potentially dangerous — or even deadly — combination.
Gastrointestinal bleeding is actually fairly commonplace, which explains why it’s among the most common Xarelto side effects. Gastrointestinal bleeding can occur in one of two areas: the upper GI tract and the lower GI tract.
The upper GI tract includes the esophagus, stomach and a portion of the small intestine. When bleeding occurs in this area, you may experience some abdominal tenderness, stomach upset which can cause the patient to vomit blood, along with darkened or even black, “tarry” stools (the blood is no longer fresh by the time it reaches the colon, hence the black, tar-like appearance.)
The lower GI tract includes the lower portion of the small intestine, the large intestine, the bowels, the rectum and the anus. When bleeding occurs in the lower gastrointestinal tract, symptoms may include a firm, painful abdomen and visible blood in feces.
Xarelto Gastrointestinal Bleeding Symptoms & Conditions
Xarelto gastrointestinal bleeding is actually amongst the most common side effects of this powerful drug.
GI bleeds can occur due to many different conditions, including:
Esophageal erosion from chronic acid reflux
Gastric or stomach ulcer bleedingRectal/anal bleeding from hemorrhoids
Bleeding intestinal polypsBleeds arising from anal fissuresCrohn’s disease-related bleeds
Bleeding from ulcerative colitis
Diverticulosis-related bleeding
Broken blood vessels in the lining of the intestine….and beyond.
In most cases, Xarelto does not trigger the gastrointestinal bleeding. Rather, the bleeding arises as a result of an underlying condition or problem. In many cases, an individual may not even realize that they’re experiencing chronic gastrointestinal bleeding. It’s a condition that can easily go undetected until the bleeding becomes moderate to severe. If Xarelto is added to the equation, it can result in a deadly condition.
Xarelto’s effects of thinning the blood create a perfect storm scenario. The anti-coagulant medication prevents blood clots from forming, so the bleeding continues indefinitely. This leads to an uncontrolled bleeding situation which can ultimately turn fatal, especially if the bleeding becomes moderate or heavy.
Xarelto Gastrointestinal Bleeding Symptoms
Symptoms of gastrointestinal bleeding on Xarelto can take a number of different forms, including:
abdominal pain
a hard abdomen
vomiting blood
bloody stool
black, tar-like stool
very pale complexion
extreme tiredness
fainting
Treatment for Xarelto gastrointestinal bleeding can be quite challenging because there is no antidote or reversal agent for this blood thinner drug.
In addition to GI bleeds, Xarelto side effects include other forms of internal bleeding, like renal (kidney) bleeding and eye bleeding, along with stroke.
If you or a loved one experienced internal bleeding or other Xarelto side effects, you could have a viable legal case against the drug’s manufacturer. Currently, as of September 2015, there are more than 1200 Xarelto lawsuits filed as part of the multi-district litigation (MDL) case that is now moving forward in the U.S. District Court for the Eastern District of Louisiana, under the direction of Judge Eldon Fallon.
Don’t delay in contacting the compassionate team here at The Meldofsky Firm, as the law limits how long you have to take action. Our legal professionals will review and evaluate your case in a prompt manner, so call The Meldofsky Firm today at 877-274-8672.
http://xareltoinjurylawsuits.info/side-effects-of-xarelto-gastrointestinal-bleeding/

Return to headline | Return to top
Florida Woman Files Xarelto Lawsuit Over Bleeding Injuries

Sep 9, 2015 | Top Class Actions

By Amanda Antell

A Florida woman filed a Xarelto lawsuit against Jansen Pharmaceuticals and Bayer Pharmaceuticals, for allegedly causing her to suffer from internal bleeding.
Plaintiff Donna M. claims in her Xarelto lawsuit that as a direct result of using the defendants’ anticoagulant, Xarelto, she developed sudden internal bleeding injuries and had to hospitalized.
Xarelto is one of three new-generation anticoagulant medications, with the others being Pradaxa and Eliquis. Each of these drugs were released and advertised to be in direct competition to each other, and their common predecessor, Warfarin.
Soon after its release in 2011, Xarelto dominated the anticoagulant market and has been prescribed to millions of patients suffering from atrial fibrillation and were at high risk for stroke occurrence.
Donna was one of these patients, and was prescribed to her by her physician after reviewing the defendants’ advertisements. Xarelto was advertised to be overtly superior to Warfarin and other new-generation anticoagulants, promising to be a safe and effective treatment against stroke.
This was proven wrong when Donna suddenly suffered uncontrollable internal bleeding injuries, and had to be immediately hospitalized. Luckily, the plaintiff survived and lived to file legal action against Bayer and Jansen Pharmaceuticals, for product liability charges.
Unfortunately, the complications Donna suffered are not uncommonly reported in the medical community, as hundreds of Xarelto bleeding reports have submitted since its release. While all anticoagulants come with the risk of internal bleeding, only Warfarin comes with an approved stopping agent.
For patients using new-generation anticoagulants, emergency medical intervention is needed to prevent the patient’s internal bleeding injuries from becoming fatal. Xarelto bleeding injuries reported include: rectal bleeding, hemorrhaging, and abdominal bleeding.
Overview of Xarelto Bleeding Complications
It is important to note that its predecessor, Pradaxa, has been facing allegations of causing the same injuries in patients. When Pradaxa was released in 2010, it had been the first anticoagulant released into the market since Warfarin.
After its manufacturing company, Boehringer Ingelheim, had reached financial success with Pradaxa, it spurred American pharmaceutical companies to try their hand in the highly exclusive, but lucrative market. This spurred the creation and release of Xarelto, which now garners billions of dollars for Bayer Pharmaceuticals and Jansen Pharmaceuticals.
While legal experts are hoping that the Pradaxa litigation is starting to settle down, lawyers predict that the legal drama surrounding Xarelto is just starting. Donna and many other patients allege that Jansen and Bayer had deliberately concealed vital safety information regarding their product in order to protect the drug’s market value.
Furthermore, medical experts criticize the defendants and other manufacturers of new-generation anticoagulants of not requiring the same dose adjustment requirement as Warfarin, where patients would have to have their physicians evaluate their condition and adjust their Warfarin dose accordingly.
Not only did Xarelto not require dose adjustments, it has no stopping agent in the event of unexpected bleeding events. Additionally, Donna states that there were no warnings or indications of Xarelto bleeding complications on the drug’s label, with the defendants providing no relevant studies.
The plaintiff’s lawyers state that the defendants had the civil responsibility of warning their client and other Xarelto patients of these complications, because they rely on the given information. Donna insists that she never would have used Xarelto, if she knew about the risk of internal bleeding.
So for being allegedly responsible for manufacturing, selling, distributing, and marketing a dangerous drug, Donna is suing Bayer and Jansen Pharmaceuticals. The charges include: negligence, false advertising, concealing information, and misrepresenting a product.
This Xarelto Lawsuit is filed In Re: Xarelto Products Liability, MDL No. 2592, in the U.S. District Court of Eastern Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/123004-florida-woman-sues-for-xarelto-bleeding-injuries/

Return to headline | Return to top
Xarelto Bleeding Lawsuit (Video)

Sep 9, 2015 | YouTube

By The Cochran Firm

The Cochran Firm published a video on YouTube that reviews the alleged side effects of Xarelto and implores viewers to contact the law firm.
Video: https://www.youtube.com/watch?v=wwt9p1yvB4E

Return to headline | Return to top
Medical Malpractice Over Medication

Sep 10, 2015 | Xarelto Lawsuit Information

These days medical malpractice has become another every day form of litigation. Given the recent news that’s come to light over the negative effects of Xarelto (rivaroxaban) mainly do to the incorrect dosing resulting in harm and death. Some victims are left to wonder if they have any ground to file a medical malpractice suit against their doctor who prescribed them the drug in the first place.
The easy response generally is no. Either by design or careless supervision, Bayer and Janssen supplied the health care profession with the same misinformation as they did to healthcare patients. The doctors have to work with the info the pharmaceutical company provides to them. As long as the doctor makes their prescribing choices based on the pharmaceutical drug guidelines the doctor cannot be held responsible for and medical malpractice.
It is a fact though that prescribing doctors knew of the likelihood of serious bleeding and risks associated with the Variable Xa anticoagulants that where new on the market. The major cause of the lawsuit is over the dosage guidelines supplied by Janssen.
For over six decades, doctors used a type of rat poison known as, warfarin, for treating patients in danger for stroke resulting from blood clots. Warfarin, a vitamin K antagonist is cheap but more importantly can be reversed if required. Patients must have their blood examined for the amount of clotting factor present – and also the dosage of warfarin must be corrected accordingly.
All a physician needed to do was determine which dosage to prescribe. This is the cause of action for today’s Xarelto litigations. Patients have bled to death While taking the medication Xarelto, do to the amount of medication the the patients system. For clotting agent degrees within their bloodstreams had patients been monitored, some who’ve perished might be alive now.
What has yet to be ascertained is whether the makers did not find the dangers when they should have, or intentionally withheld the knowledge and of Xarelto were mindful of this. This obligation lies with the producer, not the doctor who prescribed the medication in good faith.
https://www.xareltocares.com/xarelto/medical-malpractice-over-medication/

Return to headline | Return to top
New Xarelto Lawsuits Filed in 2015

Sep 11, 2015 | Xarelto Problems

21 cases from 10 districts over the blood-thinning drug Xarelto were consolidated into a multidistrict litigation (“MDL”) for pretrial proceedings before Judge Fallon in New Orleans. Meanwhile, more Xarelto lawsuits continue to mount, with 86 suits pending, according to the Judicial Panel on Multidistrict Litigation’s January 15, 2015 monthlyreport. All contend that the anticoagulant manufactured and marketed to safely and effectively clot blood has failed to do so, causing uncontrolled, sometimes fatal, bleeding. Consolidating the initial 21 suits allows the court to more efficiently address the nearly identical claims that Xarelto’s manufacturers, Bayer Healthcare and Janssen Pharmaceuticals, did not properly communicate the risks associated with Xarelto, including the fact that there is no known bleeding antidote for the drug. As the bellwether trials near, more lawsuits are likely to join the 86 suits pending in the MDL.
http://xareltoproblems.com/new-xarelto-lawsuits-filed-2015/

Return to headline | Return to top
Xarelto Lawsuit Might Just Settle In 2016

Sep 11, 2015 | Xarelto Lawsuit Information

The very first stage of the Xarelto suits was the filing of Xarelto grievances in various national and state authorities round the nation. Various sufferers have filed these charges round the state who allege that Xarelto caused them hurt somehow. The charges identify the damage, pain, and bearing the plaintiff put and summarize the legal foundation for a Xarelto suit.
Merging cases into an MDL saves judicial resources and expedite cases. An MDL additionally enables attorneys from both sides to focus more on the discovery procedure as well as the cases before resolution discussions and the first trials. This whole procedure typically takes about a complete year.
Now, there are about 1,200 cases filed in the amount event rate, the amount of suits filed is anticipated adverse of prescriptions issued and on the Xarelto MDL and based to continue to grow as litigation moves forward.
We estimate that resolution discussions will start to happen at the first in 2016. In the event the defendants choose to settle these suits, they may do so via a stock or world-wide resolution. The trials will continue to be scheduled if no Xarelto resolution is reached in 2016.
The Dangerous Anticoagulant Effects of Xarelto:
These Xarelto cases are being brought to court since the plaintiffs allege that Xarelto was the reason for their serious adverse events including uncontrollable internal bleeding which lead to death or acute injuries. In case of an internal bleeding harm, there isn’t any antidote for the effects of Xarelto, so there isn’t any solution to prevent the bleeding if a patient is bleeding. Most of the Xarelto suits allege that the makers of the drug were informed of these added hazards connected ith Xarelto and neglected to adequately warn physicians and patients.
https://www.xareltocares.com/xarelto/xarelto-settlements-might-begin-2016/

Return to headline | Return to top
Xarelto Bleeding Injury Multidistrict Litigation Adds Another Lawsuit

Sep 11, 2015 | Top Class Actions

By Tamara Burns

A Tennessee resident is the newest plaintiff to join the multidistrict litigation (MDL) against Janssen Pharmaceuticals and Johnson & Johnson’s anticoagulant drug, Xarelto.
Plaintiff Barbara M. joins thousands of plaintiffs in the Xarelto multidistrict litigation alleging the new generation blood thinner causes serious internal bleeding injuries.
Because there were so many Xarelto bleeding lawsuits filed across the country with similar drug injury claims, the cases were consolidated to the U.S. District Court in the Eastern District of Louisiana.
Multidistrict litigation allows cases to be addressed in a more streamlined manner. Less resources are used and less time is needed when fact-gathering and pre-trial hearings all happen at one location with a single judge.
This process also allows for more consistent rulings after the trials have taken place. A similar MDL took place for the drug Pradaxa (a drug similar to Xarelto), and it paid out settlements for over 4000 plaintiffs in the amount of $650 million dollars.
What is Xarelto?
Xarelto (rivaroxaban) is a blood thinning medication known as an anticoagulant. It is one of several newer generation anticoagulant drugs, along with Pradaxa and Eliquis. It is used to treat deep vein thrombosis (DVT), pulmonary embolism (PE) and is used to prevent and reduce the risk of stroke from atrial fibrillation.
Before the new generation anticoagulants, warfarin (Coumadin) was the most commonly used blood thinner. However, warfarin required frequent monitoring of its use. With the newer drugs, the monitoring was not needed as often, and it was seen as a more convenient alternative.
Xarelto and Internal Bleeding
With warfarin and other anticoagulant medications, there is a potential increased risk of bleeding complications. Yet, when warfarin is used, there is a bleeding antidote used to reverse life-threatening bleeding.
Fresh frozen plasma and intravenous vitamin K assists in stabilizing the bleeding. With Xarelto, there is no reversal agent, so the bleeding is unable to be stopped safely with an antidote. This has caused many emergency situations for new generation anticoagulant users.
Reports to the FDA of Xarelto bleeding events have increased over the last several years. 1218 reports were filed in 2012, 3600 were filed in 2013 and over 3000 were filed through the reporting period in October of 2014.
Of the new generation anticoagulants, Pradaxa was the first to be FDA approved. After a time, more and more reports of internal bleeding complications and other adverse events were reported, so doctors began to back away from prescribing Pradaxa.
Xarelto soon became the replacement drug prescribed when there were concerns over Pradaxa. With Xarelto’s recent popularity, more of these concerning bleeding reports are surfacing.
Xarelto Lawsuit Information
If you or a loved one have suffered a Xarelto injury from use of the drug, you may be entitled to legal compensation. A confidential consultation with an experienced dangerous drug attorney can help you decide your best course of action.
The Xarelto Bleeding Lawsuit is Case No. 2:15-cv-0357, U.S. District Court, Eastern District of Louisiana. The Xarelto MDL is In Re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL No. 2592, U.S. District Court, Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/130497-xarelto-multidistrict-litigation-continues-grow/

Return to headline | Return to top

Plaintiff Attorney Press Releases & Blogs - Canadian Litigation

As Xarelto Lawsuits Mount in U.S., Health Canada Announces Safety Review, Bernstein Liebhard LLP Reports

Sep 8, 2015 | PR Leap

By Bernstein Liebhard LLP

(PRLEAP.COM) September 8, 2015 - As Xarelto bleeding lawsuits (http://www.xareltolawsuit2015.com/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that regulators in Canada recently announced that they were investigating reports of liver injuries potentially associated with the new-generation blood thinner. According to a Health Canada notification issued on August 26th, the country's Vigilance Program has received 61 reports of liver injuries in patients taking Xarelto, while World Health Organization's (WHO) database showed 431 cases of liver injury. In 23 of those cases, Xarelto was the only drug used in 23 of the incidents noted in the WHO database.

Health Canada has been unable to establish a clear link between the reported liver injuries and the use of Xarelto. For the time being, the regulator is encouraging the reporting of liver-related harmful effects that may be linked to the use of Xarelto, and will continue to monitor the drug to identify and assess potential harms. Health Canada also noted that Xarelto's Canadian prescribing information explains that the medication should not be taken by people who have liver disease linked to problems with blood clotting, and have a risk of bleeding.

"Our Firm is currently representing individuals in the U.S. who allegedly experienced serious internal bleeding and other complications while using Xarelto. As such, we are monitoring any issues related to its safety with great interest," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is actively filing Xarelto lawsuits in U.S. courts, and continues to evaluate claims on behalf of individuals who allegedly suffered life-threatening internal bleeding and other dangerous complications related to its use.

Xarelto Litigation
Xarelto was initially approved by the U.S. Food & Drug Administration in 2011, and is now indicated for the prevention of strokes in people with atrial fibrillation; the treatment of deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in patients undergoing hip or knee replacement surgery. Like any blood thinner, Xarelto can sometimes cause episodes of serious internal bleeding. However, there is currently no approved antidote to reverse the drug's anticoagulant effects. Xarelto's label includes a black box warning that contains information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.

Court documents indicate that more than 1,600 Xarelto lawsuits have been filed in U.S. courts on behalf of patients who allegedly experienced uncontrollable internal bleeding and other complications related to its use. These cases include more than 1,200 that are pending in a federal multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana.( (In Re: Xarelto Products Liability Litigation, No. 2592) At least 382 claims have been filed in a mass tort litigation moving forward in Pennsylvania's Philadelphia Court of Common Pleas. (In Re: Xarelto Litigation, Case ID 150102349)

All of these complaints accuse Xarelto's manufacturers of failing to warn patients about its potential risks, and assert that the drug's sales were driven by marketing claims that positioned the medication as a superior alternative to warfarin, a blood thinner that has been on the market for decades. Among other things, lawsuits point out that internal hemorrhaging associated with warfarin can be stopped via the administration of vitamin K.

Xarelto patients who experienced life-threatening episodes of internal bleeding and other complications allegedly related to its use may be entitled to compensation for medical bills, lost wages, pain and suffering and more. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP's website, or by calling 800-511-5092 to schedule a free, no obligation case review.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.
http://www.prleap.com/pr/239050/as-xarelto-lawsuits-mount-in-us-health-canada

Return to headline | Return to top
Xarelto Lawsuit Update: Canadian Government Launches Xarelto Investigation

Sep 10, 2015 | KCEN-TV

By Marc Goldich

September 09, 2015 – /PressAdvantage/ – BloodThinnerHelp.com reports on international investigations that have been launched on Xarelto. While the number of Xarelto lawsuits in the United States court system has been steadily growing, regulators in Canada have recently announced investigations into reports of liver injuries that may be associated with Xarelto usage. A Health Canada document released on August 26 reports that they have received 61 reports of liver injuries in patients taking Xarelto and the World Health Organization’s (WHO) database showed 431 incidences of liver injury and in 23 of these cases, Xarelto was the only drug the patient was using.
A definitive link between the reported injuries and Xarelto usage has not been identified yet. Health Canada is encouraging Xarelto users to report any liver-related adverse events as they will continue to monitor the situation and prepare to respond.
Xarelto Side Effects
Xarelto was released onto the United States market after being approved by the FDA in 2011. The drug is manufactured by Bayer AG and Johnson&Johnson’s pharmaceutical unit, Janssen Pharmaceuticals. Xarelto is an anticoagulant that has been used to treat atrial fibrillation, deep vein thrombosis, and pulmonary embolism. The drug is an Xa inhibitor, making it different from traditional blood thinners such as Warfarin, the most distinct and dangerous difference being that there is no antidote to Xarelto. In the event of an internal bleeding emergency when the patient is taking Warfarin, doctors can administer vitamin K to make the blood clot again. If a patient taking Xarelto suffers from an internal bleeding event, there is no drug that can be administered to make the blood clot and the patient may experience an uncontrollable internal bleed. Xarelto currently has two black box warnings attached to it, the most strict warnings the FDA can issue to a drug short of recalling it.
Xarelto Lawsuits in the United States
At this point, more than 1,200 lawsuits have been filed in the Xarelto Multidistrict Litigation in New Orleans, Louisiana. A majority of these cases commonly allege that they experienced serious complications related to Xareto use and that Xarelto usage caused them to have an internal bleeding event which caused them some form of serious injury. These cases have been consolidated into the MDL to expedite the judicial process and save resources. There is also a mass tort group in Pennsylvania’s Philadelphia Court of Common Pleas with around 400 lawsuits filed in it. These lawsuits also allege that the manufacturers of Xarelto failed to adequately warn patients about the risks associated with Xarelto and marketed the drug as superior to Warfarin even though Warfarin has an antidote and Xarelto does not.
“We are very interested in all matters concerning the safety of Xarelto since we are currently representing clients who allegedly have been injured by the drug in the United States.” said Marc Goldich, experienced Xarelto attorney. “We encourage anyone who believes they may have been injured by Xarelto to contact us for a free case evaluation and consultation.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.kcentv.com/story/29993104/xarelto-lawsuit-update-canadian-government-launches-xarelto-investigation

Return to headline | Return to top
Canadian Xarelto Review Prompted by Liver Injury Reports

Sep 11, 2015 | Bernstein Liebhard LLP

By Sandy Liebhard

Health Canada recently revealed that it had undertaken a safety review of Xarelto, after the blood thinner had been named in dozens of liver injury reports. So far, the regulator has been unable to establish a clear link between Xarelto and those injuries, but it is encouraging doctors and patients to report any liver-related harmful affects that may be tied to its use.
The liver injury reports reviewed by Health Canada included 61 cases logged by the Canadian Vigilance Program, and another 431 included in the World Health Organization’s (WHO) database. A number of reports were also gleaned from the scientific literature. Health Canada was unable to establish any clear links with Xarelto because many of the reports collected by the databases were incomplete. In some of the cases reported in scientific literature, patients had underlying liver diseases before using Xarelto, or were taking other medications that may have contributed to their injury.
Health Canada also noted that Xarelto’s Canadian prescribing information warns against the use of the medication in people who have liver disease linked to problems with blood clotting, and who have a risk of bleeding.
U.S. Xarelto Litigation
In the U.S., Xarelto is the subject of hundreds of product liability claims filed on behalf of individuals who allegedly experienced uncontrollable bleeding and other serious complications associated with its use. The majority of these claims have been filed in a multidistrict litigation currently underway in the U.S. District Court, Eastern District of Louisiana, where trials are expected to get underway next year. Hundreds of additional cases are pending in a mass tort proceeding underway in Pennsylvania’s Philadelphia Court of Common Pleas.
In the U.S., Xarelto is approved for the prevention of strokes in people with atrial fibrillation; the treatment of deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in patients undergoing hip or knee replacement surgery. As is the case with any blood thinning medication, Xarelto can sometimes cause episodes of serious internal hemorrhaging. However, there is currently no approved antidote to reverse this occurrence. Xarelto’s label also includes a black box warning that contains information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.
Xarelto lawsuit plaintiffs charge that the drug’s manufacturers induced doctors to prescribe the medication by marketing it as a superior alternative to warfarin, a blood thinner that has been in used for decades. Among other things, they point out that bleeding from warfarin can be reversed via the administration of vitamin K.
Xarelto Lawyers Now Accepting Case Inquiries
The Xarelto lawyers at Bernstein Liebhard LLP are now accepting case inquiries from individuals who experienced dangerous internal bleeding or other complications that may be related to their use of this medication. To learn more, please call (888) 979-1182.
http://www.thexareltolawsuit.com/canadian-xarelto-review-prompted-by-liver-injury-reports/

Return to headline | Return to top
Canadian Government Launches Xarelto Investigation

Sep 10, 2015 | The National Law Review

By Stefanie Colella-Walsh

Xarelto (rivaroxaban) is a blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in July 2011 to prevent strokes in patients who received hip and knee replacements. In November 2011, the approval was expanded to any patients with atrial fibrillation (irregular heartbeat). Xarelto has been widely prescribed, with millions of people taking the medication since it entered the market.
The number of lawsuits alleging injuries associated with ingestion of Xarelto continues to grow in the United States. Regulators in Canada recently announced investigations into reports of liver injuries that may be associated with Xarelto usage. The August 26 safety review cites numerous reports of liver injuries among Xarelto users. The Canadian government will continue to monitor the safety information involving Xarelto to assess the health risks of the medication.
http://www.natlawreview.com/article/canadian-government-launches-xarelto-investigation#sthash.rTeIZIPv.dpuf

Return to headline | Return to top

Add recipients

Suggested